PTC Therapeutics, Inc.
PTCTHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States. The company carries a $6.52B market cap, placing it firmly in the mid-cap category. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.
Market Cap
$6.52B
Beta
0.53
P/E (TTM)
—
P/E (Fwd)
25.46
EPS (TTM)
$-2.54
EPS (Fwd)
$3.09
ROE
—
ROA
-1.5%
Cash
$1.89B
Total Debt
$2.72B
Free CF
-$418.1M
52W Change
65.0%
Annual Financials
Cash vs Debt
PTC Therapeutics, Inc. carries $2.72B in total debt against $1.89B in cash reserves — debt is modestly above the cash position. Managing this leverage effectively will be important for long-term financial stability. The company is burning cash, with free cash flow at -$418.1M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Revenue has grown from $698.8M (2022) to $1.73B (2025), reflecting a 148% increase over the period.
With a beta below 0.7, PTC Therapeutics, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing PTCT's risk profile alongside its fundamentals and technical indicators provides a more complete picture.